E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Recombinant human endostatin adenovirus injection is a novel anti-tumor gene therapy drug.
E10A contains a recombinant human endostatin gene with the second-generation recombinant
adenovirus as its vector. After transfection tumor cells. E10A expresses human endostatin,
which inhibits vascular endothelial cell proliferation and tumor angiogenesis, and blocks
tumor blood supply, thereby specifically inhibiting tumor growth and inducing apoposis of
tumor cells. Both pre-clinical and animal models have demonstrated the anti-tumor activities
of E10A. The safety and efficacy of E10A in treating head and neck cancer has also been
demonstrated in Phase I and Phase II studies.